KTTA (Pasithea Therapeutics Corp.) Enterprise Value-to-Revenue Coefficient

Pasithea Therapeutics Corp (KTTA) - corporate logo

The lack of stable income and risks associated with psychiatric research are weighing on shares, and consequently, the EV-to-revenue ratio on GURU.Markets reflects current volatility, with the value holding at 0.00. The prospects for Pasithea Therapeutics (KTTA) rely on the success of macrophage inhibitors and M&A potential, while updated management strictly controls operating expenses to preserve liquidity.

Pasithea - KTTA EV/Sales Multiple (period 11/23/2025 - 11/20/2026)

Pasithea Therapeutics - analytical breakdowns and key metrics (KTTA)

- business market valuation indicators:
Initial company analysis:Pasithea Therapeutics Corp
Product sample of Pasithea

The balance between developing ketamine therapy clinics and creating neurofibromatosis drugs allows Pasithea Therapeutics (KTTA) to diversify its cash flows. By analyzing the enterprise value-to-sales multiple, an investor assesses the market value of the business, including debt, relative to revenue, where a sharp increase in the indicator signals inflated growth expectations and the risk of overpayment, calling into question the sustainability of the invested capital.

Competitor analysis for Pasithea Therapeutics

BIIB (Biogen Inc.) - Company Value to Revenue Ratio|NBIX: EV/Sales Multiple|RGC (Regencell Bioscience Holdings Limited) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Axsome Therapeutics Inc|ACAD: Business Value to Revenue|EV/Sales Multiple XENE|EV/Sales Multiple vikingtherapeutics.com (VKTX)|Enterprise Value-to-Revenue Ratio Supernus SUPN|Business Value to Revenue CPRX|denalitherapeutics.com - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Harmony Pharma HRMY|BHVN: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Amylyx Pharmaceuticals, Inc. (AMLX)|TRVI (Trevi Therapeutics Inc) - EV/Sales Multiple|Company Value to Revenue Ratio PRAX (Praxis Medicines)|Enterprise Value-to-Revenue Ratio Anavex Life Sciences (AVXL)|Enterprise Value-to-Revenue Ratio CBLL (CeriBell EEG)|EV/Sales Multiple PRTA (Prothena Corp)|alector.com (ALEC) - Enterprise Value-to-Revenue Multiple|ANNX: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Omeros|NGNE: EV/Sales Multiple|Company Value to Revenue AC Immune|Company Value to Revenue VYGR|Company Value to Revenue Ratio NMRA (neumoratx.com)|Company Value to Revenue SCLX (Scilex Holding Company, Inc.)|Enterprise Value-to-Revenue Ratio TVGN (Tevogen Bio)|Enterprise Value-to-Revenue Ratio Alpha Cognition ACOG|CGTX - Company Value to Revenue|IKT - Enterprise Value-to-Revenue Ratio|SAVA: Enterprise Value-to-Revenue Ratio|Assertio Therapeutics (ASRT) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Coya Therapeutics Inc (COYA)|Enterprise Value-to-Revenue Ratio Vistagen|Company Value to Revenue Ratio OVID (ovidrx.com)|Enterprise Value-to-Revenue Ratio Acumen Pharmaceuticals, Inc. (ABOS)|CRVO - Enterprise Value-to-Revenue Multiple|Alterity Therapeutics Ltd. - Company Value to Revenue|CLNN - Company Value to Revenue|PEPG - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio jupiterneurosciences.com JUNS|Relmada Therapeutics (RLMD) - Enterprise Value-to-Revenue Ratio|ANVS (Annovis Bio, Inc.) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio gracetx.com|EV/Sales Multiple Firefly Neuroscience, Inc.|Enterprise Value-to-Revenue Ratio ANEW Medical (KLTO)|NRSN - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple RVPH (Reviva Pharmaceuticals Holdings Inc.)|Enterprise Value-to-Revenue Coefficient MTVA (metaviatx.com)|NeurAxis Inc. - EV/Sales Multiple|Total Company Value-to-Revenue Ratio heliusmedical.com HSDT|PASG: EV/Sales Multiple|Neuphoria - Business Value to Revenue|Company Value to Revenue NERV|ATHA: Business Value to Revenue|Enterprise Value-to-Revenue Ratio Addex Therapeutics Ltd (ADXN)|ALZN (Alzamend Neuro Inc.) - Business Value to Revenue|EV/Sales Multiple CYCN (cyclerion.com)|Enterprise Value-to-Sales Ratio Protagenic|CRGT - Enterprise Value-to-Revenue Ratio|Business Value to Revenue ATXI (Avenue Therapeutics)|BCLI: EV/Sales Multiple|Cara Therapeutics - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Chromocell Therapeutics Corporation|EV/Sales Multiple Eliem Therapeutics Inc.|Enterprise Value-to-Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|LBPH (Longboard Pharmaceuticals) - Business Value to Revenue|EV/Sales Multiple MRNS (marinuspharma.com)|NKGN: Company Value to Revenue Ratio|NRBO - Enterprise Value-to-Revenue Ratio|SAGE - EV/Sales Multiple|Synaptogenix (SNPX) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Trevena (TRVN)|Company Value to Revenue VIGL|Company Value to Revenue Ratio WENA (Anew Medical)|EV/Sales Multiple CERE